Introduction {#Sec1}
============

Metabolic bone diseases originate from endocrine dysfunctions as well as from heterogeneous determinants, including age, life style, and environmental influences. Bone turnover is physiologically regulated by hormones, cytokines, and growth factors and is under the control of numerous signaling pathways (Chavassieux et al. [@CR25]). Metabolic diseases may have primary or secondary impact on bone mineralization. For investigating disease development and progression and to understand the underlying mechanisms, mice have been shown to serve successfully as model organisms (e.g., Abe et al. [@CR2]; Kurima et al. [@CR65]; Marklund et al. [@CR77]; McGowan et al. [@CR81]). Random *N*-ethyl-*N*-nitrosourea (ENU) mutagenesis is a promising approach to obtain mouse models for inherited human diseases (Hrabě de Angelis and Balling [@CR54]). This has been shown in worldwide ENU mutagenesis programs, including bone metabolism, using dual-energy X-ray absorptiometry (DEXA), X-ray analysis, biochemical markers, or the SHIRPA protocol for the phenotyping of ENU mutagenesis-derived C3H/HeJ, BALB/cCRLAnn, and B57BL/6 J mice (Barbaric et al. [@CR13]; Smits et al. [@CR100]; Srivastava et al. [@CR104]).

Within the large-scale Munich ENU mutagenesis screen more than 850 mutant mouse lines have been isolated, derived from a large-scale genome-wide screen (Hrabě de Angelis et al. [@CR55]) or from an implemented modifier screen on *Dll1*^*lacZ*^ knockout mice (Rubio-Aliaga et al. [@CR95]). Our Dysmorphology Screen is focusing on the isolation of new mouse models for hereditary metabolic bone diseases (Fuchs et al. [@CR45]; Lisse et al. [@CR67]).

In previous studies in mice the reliability of biochemical markers for skeletal disorders, including alkaline phosphatase (ALP), has been shown (Srivastava et al. [@CR103]). Combined ALP, total calcium (Ca), and inorganic phosphate (P~i~) measurements in serum or plasma are routinely performed in patients with metabolic bone diseases (Table [1](#Tab1){ref-type="table"}).Table 1Mouse models for metabolic bone diseases with altered ALP activity and Ca and P~i~ values in plasma and corresponding human diseases with equivalent changesMouse models\*ALPCaP~i~Human disease^A^Fgf23^R176Q^↑^a^Ø^a^↓^a^Autosomal dominant hypophosphatemic rickets (ADHR)^B^Dmp1^tm1.1Mis^, ^C^DMP1^tm1Jqf^↑^b^Ø^b^↓^c^Autosomal recessive hypophosphatemic rickets (ARHR)^D^Slc34a3^tm1Kimi^↑^d,\ e^Ø^f,\ g^↓^e,\ g^Hereditary hypophosphatemic rickets with hypercalciuria (HHRH)^E^Phex^Hyp−2J^, ^E^Phex^Hyp-Duk^, ^F^Phex^Hyp^ Gy, Ska1, Pug, ^L^BAP012, ^L^BAP024↑↑^h^Ø↓^b^X-linked hypophosphatemic rickets (XLHR)^G^Alpl^Hpp^, ^H^Alpl^tm1(cre)Nagy^, ^I^Alpl^tm1Jlm^, ^K^Alpl^tm1Sor^, ^L^BAP020, ^L^BAP023, ^L^BAP026, ^L^BAP027, ^L^BAP032↓^h,\ i^↑^k^Ø-↑^k^Hypophosphatasia (HPP)e.g., ^M^Col1a1^Aga2^, ^N^Col1a2^oim^, ^O^Col1a1^Mov13^, ^P^Col1a1^Tm1Jae^↑^l,\ m^ØnOsteogenesis imperfecta^Q^Vcp^tm1Igl^↑↑^i^Ø^n^-↑^o^Ø^p^Paget's disease of bone (PDB)^R^Casr^tm1Ces^, ^L^BCH002, ^L^BCH003, ^L^BCH004, ^L^BCH007, ^L^BCH011, ^L^BCH013, ^L^BCH014Ø↑^q,r^↓^q,r^Primary hyperparathyroidism*Ø* unchanged, *↑* increased, *↓* decreased, *n* no data, *ALP* alkaline phosphatase, *Ca* total calcium, *P* ~*i*~ total inorganic phosphate^a^Econs and McEnery ([@CR35]), ^b^Lorenz-Depiereux et al. ([@CR71]), ^c^Lorenz-Depiereux et al. ([@CR73]), ^d^Mejia-Gaviria et al. ([@CR82]), ^e^Lorenz-Depiereux et al. ([@CR72]), ^f^Delmas ([@CR31]), ^g^Tieder et al. ([@CR108]), ^h^Mornet et al. ([@CR84]), ^i^Whyte ([@CR113]), ^k^Chodirker et al. ([@CR27]), ^l^Cundy et al. ([@CR28]), ^m^Braga et al. ([@CR19]), ^n^Singer et al. ([@CR98]), ^o^Freeman ([@CR44]), ^p^Goseki-Sone et al. ([@CR49]), ^q^Bilezikian et al. ([@CR17]), ^r^Tiosano and Hochberg ([@CR109])^A^Farrow et al. ([@CR38]), ^B^Feng et al. ([@CR40]), ^C^Feng et al. ([@CR39]), ^D^Segawa et al. ([@CR96]), ^E^Lorenz-Depiereux et al. ([@CR70]), ^F^Eicher and Southard ([@CR36]), ^G^Hough et al. ([@CR53]), ^H^Lomeli et al. ([@CR69]), ^I^Narisawa et al. ([@CR87]), ^K^MacGregor et al. ([@CR74]), ^L^Table [4](#Tab4){ref-type="table"}, ^M^Lisse et al. ([@CR67]), ^N^Chipman et al. ([@CR26]), ^O^Bonadio et al. ([@CR18]), ^P^Liu ([@CR68]), ^Q^Badadani et al. ([@CR12]), ^R^Ho et al. ([@CR50])

Ca and P~i~ homeostasis is balanced by intestinal absorption, mobilization, or binding in bone and renal excretion. Ca levels directly and indirectly influence intestinal phosphate absorption. Much less is known about the influences on P~i~ homeostasis (Bergwitz and Jüppner [@CR16]). A key role in maintaining phosphate homeostasis is the reabsorption of phosphate from urine into the renal proximal tubules. A previously identified phosphaturic factor, FGF23 (fibroblast growth factor 23), acts as an endocrine hormone on the regulation of P~i~ reabsorption in the kidney and on renal vitamin D metabolism (ADHR Consortium [@CR4]; Strom and Jüppner [@CR105]).

Here we describe the results of the Munich ENU Mutagenesis Project to obtain new mutant mouse models for impaired bone metabolism by phenotyping for alterations of at least one of the described plasma parameters as selection markers. We isolated 71 new murine models that may be of special value for the development of new therapeutic approaches since a high number of metabolic bone diseases in human patients are caused by point mutations (Marini et al. [@CR76]; Simon-Bouy et al. [@CR97]; Wenkert et al. [@CR112]).

Material and methods {#Sec2}
====================

Mice {#Sec3}
----

For this study we used C3HeB/FeJ (C3H) inbred mice purchased originally from the Jackson Laboratory (Bar Harbor, ME, USA) and bred in our animal facility. The mice were housed and handled according to the federal animal welfare guidelines and the state ethics committee approved all animal studies. The mice were kept in a 12/12-h dark--light cycle and provided standard chow ad libitum (TPT total pathogen-free chow \#1314: calcium content 0.9 %, phosphate 0.7 %, vitamin D3 600 IE; Altromin, Lage, Germany) and water. Hygienic monitoring was performed following FELASA recommendations (Nicklas et al. [@CR88]). Mutant mouse lines derived from our screen were given internal lab codes and were assigned with official gene symbols and names after the mutation was identified.

ENU mutagenesis {#Sec4}
---------------

ENU mutagenesis treatment of inbred strain C3H males was as described previously (Aigner et al. [@CR8]). Litters produced from the ENU-treated C3H males (G0) are designated F1 in the following, while offspring produced from confirmed mutant F1 animals are designated G2.

Generation of F1 mice and confirmation of phenotypes in a dominant breeding strategy {#Sec5}
------------------------------------------------------------------------------------

The F1 animals investigated for this study were derived from a total of 893 G0 males from 15 different ENU-treated groups. Blood samples of 9,540 F1 animals (4,606 females and 4,934 males) were screened for alterations of total ALP, Ca, and P~i~ blood plasma levels. F1 mice showing alterations of blood-based parameters were retested after 14 days. Breeding for confirmation of a dominant phenotype was performed as described previously (Aigner et al. [@CR5]).

Blood measurements {#Sec6}
------------------

Blood samples (250 μl) were obtained from 12-week-old nonfasted anesthetized mice by puncture of the retro-orbital sinus, as already described (Rathkolb et al. [@CR93]). All samples were collected between 9:00 and 11:00 a.m. Plasma analysis of ALP, Ca, and P~i~ was done using an Olympus AU400 autoanalyzer (Olympus, Hamburg, Germany) and adapted test kits (Klempt et al. [@CR63]). Descriptive data are expressed as mean ± standard deviation. PTH values were analyzed with a Mouse Intact PTH ELISA Kit (TECOmedical, Bünde, Germany).

DXA and X-ray measurement {#Sec7}
-------------------------

DXA (pDEXA Sabre, Norland Medical Systems Inc., Basingstoke, Hampshire UK, distributed by Stratec Medizintechnik GmbH, Pforzheim, Germany) and X-ray (Faxitron, Hewlett Packard, Palo Alto, CA, USA) measurements were performed for in-depth analysis in selected mouse lines as described previously (Abe et al. [@CR1]; Fuchs et al. [@CR46]).

Genetic mapping {#Sec8}
---------------

To map the mutations, ENU-derived mutant mice were outcrossed to wild-type C57BL/6 J (B6) mice, as described previously (Aigner et al. [@CR7]). For linkage analysis, SNP (single-nucleotide polymorphism) genotyping by high-throughput MALDI-TOF (matrix-assisted laser desorption/ionization time-of-flight) technology supplied by Sequenom (San Diego, CA, USA) was performed with a panel containing 158 markers evenly distributed over the whole genome (Klaften and Hrabě de Angelis [@CR62]). We developed the internal MyGenotype database for statistical SNP data analysis.

Mutation analysis {#Sec9}
-----------------

*Casr*, *Phex*, *Alpl*, and *Asgr1* exons were amplified with intronic primers and directly sequenced using BigDye v3.1 cycle sequencing (Applied Biosystems, Life Technologies, Foster City, CA, USA). *Casr* consists of 7 exons (NM013803), *Phex* (NM011077) consists of 22 exons, and *Alpl* (NM007431) consists of 12 exons. All primer sequences are available upon request. The mutation of the BAP005 mutant line was detected by chromosome sorting (CHROMBIOS, Raubling, Germany) and whole-chromosome sequencing on a Genome Analyzer IIx (Illumina, San Diego, CA, USA). DNA extraction from sorted chromosomes 11 was performed overnight at 42 °C with 0.25 M EDTA, 10 % Na lauroyl sarcosine, and 50 μg proteinase K. Extracted DNA was precipitated and resuspended in TE buffer. Paired-end libraries were constructed with the Illumina paired-end DNA sample preparation kit according to the manufacturer's protocols and as described previously (Eck et al. [@CR34]). Alignment of the reads was performed with the BWA software, and subsequent analysis was performed with the SAMtools package. In total, \~82 million reads and \~157 million reads were generated for the mutant and control strain, respectively, of which 64 % mapped to the target chromosome 11 for the mutant strain, while 26 % of the control strain reads were on target. The identified nonsynonymous sequence variation in *Asgr1* was confirmed in mutant mice by capillary sequencing.

Statistical analysis {#Sec10}
--------------------

Statistical analysis of parameters of F1 animals and sex- and age-matched wild-type C3H mice were performed using the software package JMP Release 5.1 (SAS Institute, Cary, NC, USA). The reference values were obtained from untreated age-matched C3H wild-type control groups (50 males and 50 females). Single F1 variants for ALP activity and Ca levels were defined by a *Z* score ≥3 or ≤--3 compared to the age-matched control groups. Mice showing hypophosphatemia were tested three times to confirm P~i~ changes. A *Z* score of ≤--2 was taken to select variants for hypophosphatemia. Statistical differences (*P* values) of the means of ALP, Ca, or P~i~ blood values between all tested affected mice and nonaffected littermates of a mutant line were assessed by one-way analysis of variance (ANOVA), *t* test (giving mean ± SD values), and the Mann-Whitney rank sum test (giving median values) using SigmaStat 3.5 (Systat Software Inc., Chicago, IL, USA).

Results {#Sec11}
=======

Overall results and statistics {#Sec12}
------------------------------

In order to identify early stages of disturbed bone turnover, we investigated the diagnostic value of routine assays for ALP activity and Ca and P~i~ levels in the plasma of mice derived from ENU-treated males for its comparability to their use in human patients (Table [1](#Tab1){ref-type="table"}). This table also shows other mouse lines obtained for selected metabolic bone diseases and the observed alterations of plasma parameters in these models. Since we were interested only in mouse lines showing alterations of the bone ALP (bALP) isoform of the measured total ALP enzyme, variants with additional alterations of ALAT (alanine-amino-transferase) and ASAT (aspartate-amino-transferase) levels were excluded from this study.

Two hundred fifty-seven phenodeviants (2.7 %, 87 females and 170 males) of 9,540 F1 animals showed alterations in at least one of the three parameters of interest (ALP, Ca, and P~i~) in two repeated blood measurements. One hundred ninety of the 257 (74 %) phenodeviants were mated to wild-type C3H mice in confirmation crosses. In 71 of the mated 190 (37 %) (25 females and 46 males), the observed phenotype was genetically transmitted as a dominant trait (Table [2](#Tab2){ref-type="table"}); however, six of these mutant lines were lost because no mutant male offspring was produced for sperm cryopreservation. For 110 of the mated 190 (58 %) phenodeviants, inheritance could not be confirmed because of sterility (*n* = 22/110, 20 %), the mice died due to unknown reasons (*n* = 15/110, 14 %), or the hypothesis of a dominant mutation was excluded (*n* = 73/110, 66 %). Confirmation crosses for the remaining 9 of the 190 phenodeviants are still underway. Sixty-seven of the 257 (26 %) phenodeviants were not mated due to space limitations; however, their sperm was frozen. Founder F1 mice with a similar phenotype and derived from the identical G0 male were expected to carry the identical mutation. Fifteen mutations have been identified resulting in new alleles of the *Phex*, *Casr*, and *Alpl* genes (Table [3](#Tab3){ref-type="table"}).Table 2Genetic confirmation crosses and confirmed mutations for F1 variants with alterations of ALP activity and/or Ca and P~i~ plasma valuesPhenotype^a^Confirmation crossesALPCaP~i~Total numberConfirmed (% of total F1 tested for this phenotype)Ongoing↑ØØ8328 (33.7)1↑↑Ø42 (50)0↑↑↑100↑↑↓11 (100)0↑↓Ø11 (100)0↑Ø↓144 (28.6)1↓ØØ106 (60)1↓Ø↓100Ø↑Ø209 (45)0Ø↑↑100Ø↑↓84 (50)2Ø↓Ø31 (33)0ØØ↑21 (50)0ØØ↓4114 (34.1)4Total19071 (37.4)9*↑* high, *↓* low, *Ø* unchanged, *ALP* alkaline phosphatase, *Ca* total calcium, *P* ~*i*~ total inorganic phosphateTable 3Confirmed mutant mouse lines with alterations of ALP activity and Ca and P~i~ plasma valuesLine nameVariant phenotypeAdditional phenotype, commentTransmission (%)^a^BAP001High ALP\<20BAP002High ALP, high CaAll variants with brittle teeth, jaw abnormality (\~3 months old); changes in the tubular bone structure, reduced bone density64BAP003High ALP, high CaMapped on Chr 4 between SNP markers rs28307021 and rs3711383 (101.16--141.90 Mb, mouse genome Build 37.1, UCSC)62BAP004High ALP and/or high Ca and/or low P~i~All variants with auricle degeneration when \>4 months old; reduced body size; mapped on Chr 4 between SNP markers rs28056583 and rs13469808 (86.81--117.55 Mb, mouse genome Build 37.1, UCSC)75BAP005High ALPMutation of the *Asgr1* (asialoglycoprotein receptor 1) gene, c.815A \> G; p.Tyr272Cys92BAP006High ALPIdentical G0 as BAP007lostBAP007High ALPIdentical G0 as BAP006; counted with BAP006 as one linelostBAP008High ALPIdentical G0 as BPL00171BAP009High ALPAll variants show circling behavior, reduced body size32BAP010High ALPlostBAP011High ALP32BAP012High ALP, low P~i~All variants small with shortened hind limbs, circling behavior. Nonsense mutation in exon 2 of the *Phex* (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) gene, c.148A \> T; p.Lys50X100BAP013High ALP27BAP014High ALPSignificantly more males born and affected; offspring of heterozygous intercrosses with reduced body size, ALP very high; mapped on Chr 9 between SNP markers rs3023207 and rs3673055 (37.50--96.23 Mb, mouse genome Build 37.1, UCSC)60BAP015High ALPlostBAP016High ALP70BAP017High ALPAll variants with reduced body size\<20BAP018High ALP96BAP019High ALP29BAP020Low ALPSynonymous sequence variation in exon 10 of the *Alpl* (alkaline phosphatase, liver/bone/kidney) gene, c.1098A \> T, p.Thr365Thr100BAP021High ALPHigh ALAT and ASAT, phenotype probably liver dependent44BAP022High ALP100BAP023Low ALPMissense mutation in exon 7 of the *Alpl* (alkaline phosphatase, liver/bone/kidney) gene, c.755T \> G; p.Leu251Pro. Identical G0 animal as BAP021 and BCH009100BAP024High ALP, low P~i~All variants with reduced body size, circling behavior. Missense mutation in exon 22 of the *Phex* (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) gene, c.2197T \> C; p.Cys733Arg100BAP025High ALP100BAP026Low ALPSplice site mutation in intron 9 of the *Alpl* gene (alkaline phosphatase, liver/bone/kidney) gene c.997+2T \> G85BAP027Low ALPMissense mutation in exon 10 of the *Alpl* (alkaline phosphatase, liver/bone/kidney) gene, c.1194T \> A, p.Ile395Asn100BAP028High ALPAll mutants with reduced body size100BAP029High ALP30BAP030High ALPAll mutants with reduced body size56BAP031High ALP52BAP032Low ALPMissense mutation in exon 11 of the *Alpl* (alkaline phosphatase, liver/bone/kidney) gene, c.1217A \> G, p.Asp406Gly90BCH001High Ca\<20BCH002High Ca, low P~i~Missense mutation in exon 7 of the *Casr* (calcium-sensing receptor) gene, c.2579T \> A; p.Ile859Asn. Some intercrosses derived offspring with reduced body size, gray fur100BCH003High CaMissense mutation in exon 3 of the *Casr* (calcium-sensing receptor) gene, c.295G \> T, p.Asp99Tyr. Identical G0 as BCH006100BCH004High CaNonsense mutation in exon 4 of the *Casr* (calcium-sensing receptor) gene, c. 366G \> T, p.Glu456X93BCH005High Ca22BCH006High CaIdentical G0 as BCH003; counted with BCH003 as a single line100BCH007High CaMissense mutation in exon 4 of the *Casr* (calcium-sensing receptor) gene, c.626T \> C; p.Val208Ala. Some intercrosses derived offspring show reduced body size.74BCH008High Ca78BCH009High CaIdentical G0 animal as BAP021 and BAP023\<20BCH010High Ca20BCH011High CaNonsense mutation in exon 7 of the *Casr* (calcium-sensing receptor) gene, c.2017C \> T, p.Gln673X100BCH012High Ca\<20BCH013High CaMissense mutation in exon 3 of the *Casr* (calcium-sensing receptor) gene, c.296A \> G, p.Asp99Gly100BCL001Low Ca, high ALP100BCL002Low Ca50BPH001High P~i~lostBPL001Low P~i~Identical G0 animal as BAP008\<20BPL002Low P~i~Mapped on Chr 16 between SNP markers rs4186801 and rs4199268 (51.47--69.80 Mb, mouse genome Build 37.1, UCSC)38BPL003Low P~i~\<20BPL004Low P~i~Mapped on Chr 3 between SNP markers rs13477178 and rs13477321 (69.55--109.00 Mb, mouse genome Build 37.1, UCSC)63BPL005Low P~i~46BPL006Low P~i~All mutants with reduced body size; mapped on Chr 14 between SNP markers rs30406796 and rs30865397 (22.92--74.08 Mb, mouse genome Build 37.1, UCSC)73BPL007Low P~i~All mutants with reduced body size53BPL008Low P~i~All mutants with reduced body size; mapped on Chr 8 between SNP markers rs13479952 and rs13479998 (103.43--116.69 Mb, mouse genome Build 37.1, UCSC)37BPL009Low P~i~40BPL010Low P~i~100BPL011Low P~i~67BPL012Low P~i~50BPL013Low P~i~50BPL014Low P~i~100SAP003High ALP\<20SAP004Low Ca, low P~i~\<20SAP005High ALPlostSAP006High ALP41SAP007Low ALPMissense mutation in exon 12 of the *Alpl* (alkaline phosphatase, liver/bone/kidney) gene, c.1357A \> G; p.Thr453Ala100SAP008High ALP62SCA001High Ca49SMA010High ALP, high CaAll variants with reduced body size (*Z* score \< --2)31TRE002High ALPAll mutants trembling, high ALP probably secondary effect100All mouse lines listed in alphabetical order of the internal lab names^a^According to dominant inheritance 50 % mutant offspring corresponds to 100 % transmission of the phenotype

New mouse lines carrying mutations of the *Phex* (phosphate-regulating gene with homologies to endopeptidases on the X-chromosome) gene {#Sec13}
---------------------------------------------------------------------------------------------------------------------------------------

Affected animals of the BAP012 ([B]{.ul}one screen [A]{.ul}lkaline [P]{.ul}hosphatase No. [012]{.ul}) mutant line displayed a significant (*P* ≤ 0.001) decrease in plasma P~i~ levels. Female mutant mice (*n* = 42) exhibited a P~i~ value of 1.3 ± 0.2 mmol/l compared to female wild-type mice (2.0 ± 0.3 mmol/l, *n* = 11). Male mutant mice (*n* = 7) had a P~i~ value of 1.2 ± 0.1 mmol/l compared to 2.0 ± 0.3 mmol/l in male wild-type mice (*n* = 44). Mean ALP activity was significantly elevated (*P* ≤ 0.001) in female mutants (266.4 ± 35.3 U/l) compared to wild-type littermates (147.9 ± 17.9 U/l), and also in mutant male mice (370.9 ± 88.5 U/l) compared to their wild-type littermates (120 ± 8.5 U/l). In addition to these biochemical alterations, all mutants showed reduced body size, shortened hind limbs, and mild head-tossing behavior as described in other *Phex* mouse models (Lorenz-Depiereux et al. [@CR70]; Moriyama et al. [@CR83]). Genetic crosses revealed X-linked inheritance of the phenotype. Thus, mutant mice of both sexes were derived from mated mutant females, but from matings of male mutants only female mutants were born. Based on the phenotypic data, the causative mutation was hypothesized to be in the *Phex* gene. DNA sequence analysis of the *Phex* gene revealed a new hemizygous nonsense mutation in exon 2 (c.148A \> T, p.Lys50X) (Fig. [1](#Fig1){ref-type="fig"}a). The mutation is located within the large extracellular domain of the protein close to the transmembrane domain. The *Phex* gene in mice is syntenic to the human *PHEX* gene, which is organized into 22 exons and encodes a type II transmembrane protein with homology to zinc metallopeptidases (HYP Consortium [@CR56]). Inactivating mutations of the *PHEX* gene cause X-linked dominant hypophosphatemic rickets (XLHR), which has an incidence of 1:20,000 and is the most common familial form of hypophosphatemic rickets in humans (Burnett et al. [@CR22]; Tenenhouse [@CR107]).Fig. 1**a** DNA sequence analysis of the *Phex* gene exon 2 revealed a hemizygous nonsense mutation (c.148A \> T, p.Lys50X) in the DNA of a male C3Heb/FeJ-Phex^BAP012^ mutant mouse leading to a premature translation stop codon after 49 amino acids. **b** DNA sequence analysis of the *Phex* gene exon 22 revealed a hemizygous missense mutation (c.2197T \> C, p.Cys733Arg) in the DNA of a male C3Heb/FeJ-Phex^BAP024^ mutant mouse. Variants are marked by an *asterisk*

Mice of the BAP024 mutant line express similar phenotypes, with gender influences on inheritance as the C3Heb/FeJ-Phex^BAP012^ mice. In BAP024 we found a new missense mutation in exon 22 of the *Phex* gene (c.2197T \> C, p.Cys733Arg) (Fig. [1](#Fig1){ref-type="fig"}b), also located in the large extracellular catalytic domain of the protein. The cysteine at position 733 is highly conserved among other vertebrate species (Du et al. [@CR32]). A cysteine-to-serine substitution at the corresponding position of the C3Heb/FeJ-Phex^BAP024^ mutation has been described recently in a patient with XLHR (Filisetti et al. [@CR42]). No spontaneous *Phex* point mutations on the C3H strain have been isolated previously.

New mouse lines carrying mutations of the *Casr* (calcium-sensing receptor) gene {#Sec14}
--------------------------------------------------------------------------------

The BCH002 ([B]{.ul}one screen [C]{.ul}alcium [H]{.ul}igh No. [002]{.ul}) line showed a statistically significant increase of Ca levels in mutant animals compared to wild-type littermates (*P* ≤ 0.001). Female mutants' Ca level was 2.9 ± 0.1 mmol/l (*n* = 23) compared to 2.43 ± 0.1 mmol/l for wild-type littermates (*n* = 19). The male mutant value was 2.87 ± 0.1 mmol/l (*n* = 20) compared to the wild-type littermates' value of 2.41 ± 0.1 mmol/l (*n* = 20). Fifty-three percent of female and male mutant BCH002 mice had slightly reduced P~i~ levels. Histological analysis showed enlarged parathyroid glands in heterozygous mutant mice (Fig. [2](#Fig2){ref-type="fig"}a). A group of 11 female (6 mutants, 5 wild types) and 20 male mice (10 mutants, 10 wild types) was tested for PTH values, resulting in significantly raised median PTH values for mutant mice (*P* ≤ 0.001): female mutants, 214.9 pg/ml (25 % 203.3 pg/ml and 75 % 265.7 pg/ml), and wild types, 85.7 pg/ml (25 % 79.6 pg/ml and 75 % 113.1 pg/ml). Male mutants showed 235 pg/ml (25 % 191 pg/ml and 75 % 409.9 pg/ml) compared to wild types showing 102.7 pg/ml (25 % 78.8 pg/ml and 75 % 117.2 pg/ml). So far eight pups were derived from a first heterozygous intercross but no homozygous mutant was found. Mapping analysis of 40 mutant and 20 wild-type BCH002 animals derived from the dominant backcrosses to the B6 strain revealed linkage to chromosome 16 (Table [4](#Tab4){ref-type="table"}), with the highest χ^2^ value at the marker rs4186801 (51.47 Mb, mouse genome Build 37.1, UCSC). In this region *Casr* was the most promising candidate gene for the observed phenotype. DNA sequence analysis of the *Casr* gene revealed a new heterozygous missense mutation (c.2579T \> A, p. Ile859Asn) within the protein-coding region of exon 7 (Fig. [2](#Fig2){ref-type="fig"}b) of the gene that was not present in wild-type C3H and B6 mice. CASR belongs to the family of G-protein-coupled receptors (GPCRs) and is an integral membrane protein that senses changes in the extracellular calcium concentration to parathyroid cells.Fig. 2**a** Representative pictures of the histological changes found in the mutant mouse line BCH002: **1**, **2** (*left*) depict a H&E-stained section of normal thyroid gland (T) and parathyroid gland (P) in a control mouse. In **1** (low-magnification panel, 5×, scale bar = 100 μm), the normal gland appears as a small compact mass of dark cells. In **2** at higher magnification (20×, scale bar = 20 μm), two cell types interspersed with capillaries and sinusoids are identified: the chief cells, with a small basophilic cytoplasm, and the light cells, with abundant light cytoplasm. **3**, **4** (*right*) show a H&E-stained section of the normal thyroid gland (T) and the enlarged parathyroid gland (P) with loose structure observed in heterozygous C3HeB/FeJ-Casr^BCH002^ mutant mice (**3**). At higher magnification in **4**, an increase in the number of light cells is observed. **b** DNA sequence analysis of the *Casr* gene of C3HeB/FeJ-Casr^BCH002^ mice revealed a heterozygous mutation in exon 7 (c.2579T \> A, p.Ile859Asn) that is marked by an *asterisk*Table 4Statistical analysis of SNP mapping data of the C3HeB/FeJ-Casr^BCH002^ mutant line obtained by MyGenotype databaseChromosome (marker)Highest χ^2^Highest -log10(P)1 (rs31593281)5.571.742 (rs3691120)1,800.753 (rs3685081)1.720.724 (rs28307021)0.780.425 (rs32067291)3.601.246 (rs13478606)3.761.287 (rs13479476)1.090.538 (rs13479998)8.022.349 (rs3023207)5.001.6010 (rs13480484)4.451.4611 (rs27000576)9.382.6612 (rs6194112)7.362.1813 (rs29566800)4.451.4614 (rs30482696)2.170.8515 (rs13482484)9.382.6616 (rs4186801)28.176.9617 (rs13483097)4.791.5418 (rs13483484)0.820.4419 (rs6339594)2.691.00

In addition, six new alleles of the *Casr* gene were isolated in other mouse lines (BCH003, BCH004, BCH007, BCH011, BCH013, and BCH014) (Table [3](#Tab3){ref-type="table"}) creating an allelic series for functional analysis of the gene. Median PTH levels were significantly increased (*P* *=* 0.010) in first testings of BCH013 female mutants (*n* = 6), showing 175.2 pg/ml (25 % 143.21 pg/ml and 75 % 198.33 pg/ml) compared to wild types (*n* = 4) showing 50.061 pg/ml (25 % 48.805 pg/ml and 75 % 56.962 pg/ml). Male mutants (*n* = 10) displayed 100.984 ± 30.765 pg/ml and wild types (*n* = 9) 55.485 ± 14.734 pg/ml. For all other mouse lines with mutations of the *Casr* gene, PTH data are underway. The missense and nonsense mutations of these mouse lines were located in exons 3, 4, 5, and 7 of the *Casr* gene (Table [3](#Tab3){ref-type="table"}).

New mouse lines carrying mutations of the *Alpl* (alkaline phosphatase, liver/bone/kidney) gene {#Sec15}
-----------------------------------------------------------------------------------------------

In mutant mice of the BAP032 line, statistically significant (*P* \< 0.001) low mean ALP activity was found in female mutants (47 ± 5.8 U/l, *n* = 9) compared to wild-type littermates (157.8 ± 7.9 U/l, *n* = 8), and in male mutants (38.4 ± 6.3 U/l, *n* = 12) compared to wild-type littermates (129.5 ± 10.1 U/l, *n* = 10) (Fig. [3](#Fig3){ref-type="fig"}a). Significantly reduced ALP activity suggested a mutation in the *Alpl* gene encoding the tissue nonspecific ALP (TNSALP). We sequenced this gene in BAP032 mice and revealed a new heterozygous missense mutation in exon 11 located within the protein-coding region of the *Alpl* gene on chromosome 4 (c.1217A \> G, p.Asp406Gly) (Fig. [3](#Fig3){ref-type="fig"}b). This mutation was not found in wild-type C3H littermates or in wild-type B6 mice. We isolated five additional mouse lines carrying new alleles of the *Alpl* gene (Table [3](#Tab3){ref-type="table"}). Four sequence variations were located in exons 7, 10, or 12 (BAP020, BAP023, BAP027, SAP007) and one affects the splice site in intron 9 (BAP026).Fig. 3**a** C3HeB/FeJ-Alpl^BAP032^ ALP blood activities (mean ± SD U/l) in female mutant (*N* = 8), female wild-type (*N* = 9), male mutant (*N* = 12), and male wild-type (*N* = 10) mice. Mean ± SD ALP activities were: female mutants 47 ± 5.8 U/l (*P* \< 0.001); female wild-types 157.8 ± 7.9 U/l; male mutants 38.4 ± 6.3 U/l (*P* \< 0.001); male wild-types 129.5 ± 10.1 U/l (*t*-test). **b** DNA sequence analysis of the *Alpl* gene exon 11 revealed a new heterozygous missense mutation (c.1217A \> G, p.Asp406Gly). Variant is marked by an *asterisk*

Other mouse lines and mutations {#Sec16}
-------------------------------

Female and male mutant mice of the BAP005 line showed statistically significant (*P* ≤ 0.001) increased mean ALP activity. The value in female mutants (*n* = 25) was 233 ± 21 U/l compared to 136 ± 14 U/l in wild-type littermates (*n* = 32), and in male mutants (*n* = 39) ALP activity was 188 ± 19.81 U/l compared to 104.5 ± 10.43 U/l in their wild-type littermates (*n* = 36). The mouse line breeds homozygous offspring with very high ALP activities. Homozygous females derived from heterozygous intercrosses showed mean ALP activity of 587 ± 39 U/l (*n* = 12), and ALP activity in homozygous males was 482 ± 51 U/l (*n* = 21). SNP mapping revealed a region between the markers rs26982471 and rs27000576 (53.99--114.33 Mb, mouse genome Build 37.1, UCSC) on chromosome 11. Sorting of chromosome 11 and whole chromosome 11 sequencing on a GAIIx next-generation sequencing machine revealed a new missense mutation in the *Asgr1* (asialoglykoprotein receptor 1) gene within the translated region (c.815A \> G, p.Tyr272Cys). The mutation was sequenced in 16 BAP005 mutant mice, but neither in 4 wild-type littermates, nor in additional 4 wild-type mice from different inbred strains (BALB/c, DBA/2, FVB, SJL).

For eight additional mouse lines (BAP002, BAP003, BAP004, BAP014, BPL004, BPL006, BPL008, and TRE002) showing high ALP activity, low P~i~, and high or low Ca values as a phenotype, genetic mapping has been finished (Table [3](#Tab3){ref-type="table"}) and sequencing of candidate genes is in progress. For selected mouse lines we will include exome sequencing to find the causative mutation.

Discussion {#Sec17}
==========

In this study we described a large-scale ENU mutagenesis screen (Soewarto et al. [@CR102]), with the main focus on malfunctioning bone turnover. In other projects murine models for disturbed bone metabolism were obtained by gene targeting (Daroszewska et al. [@CR30]; Ducy et al. [@CR33]; Forlino et al. [@CR43]; Kato et al. [@CR61]), transgene insertions (Imanishi et al. [@CR57]; Rauch et al. [@CR94]) or spontaneous mutations (Eicher et al. [@CR37]; Marks and Lane [@CR78]). Here, we isolated 71 new mouse models by screening for alterations of total ALP activity and total Ca and P~i~ values in plasma of 9,540 F1 mice. Our results demonstrate that malfunctions of bone metabolism in mice may be efficiently detected by the analysis of human standard clinical chemical parameters.

In this study the highest fraction of new mouse lines revealed alterations of total ALP activity (Table [3](#Tab3){ref-type="table"}). Since these mouse lines discriminated in phenotype expression and occurrence of additional phenotypes, the phenotypes presumably depend on different molecular mechanisms. Total ALP was chosen as a parameter of interest since elevated ALP activity is the most frequently measured parameter for human Paget's disease (Langston and Ralston [@CR66]), X-linked hypophosphatemic rickets (XLHR) (Jonsson et al. [@CR60]; Mäkitie et al. [@CR75]), autosomal dominant hypophosphatemic rickets (ADHR) (Econs and McEnery [@CR35]; Imel et al. [@CR58]; Kruse et al. [@CR64]), and type I osteoporosis (Avbersek-Luznik et al. [@CR11]; Pedrazzoni et al. [@CR90]).

Screening for alterations of total Ca and P~i~ values without changes of ALP activity resulted in 34 mutant lines with confirmation of the observed phenotype (Table [2](#Tab2){ref-type="table"}). While the Ca parameter was easy to measure, P~i~ values were artificially elevated after plasma storage for longer than 1 day, freezing of the samples, or hemolysis. Metabolic bone diseases may be reflected in changes of more than one parameter, and very often two or three of the parameters of interest showed alterations in the same individual mouse line, as is commonly observed in human patients (Table [1](#Tab1){ref-type="table"}).

In our screen we obtained new mouse models for hypophosphatemia, hyperparathyroidism, and hypophosphatasia. Despite the large number of existing mouse models for XLHR, there are still open questions on the mechanism of PHEX in renal phosphate wasting, abnormal vitamin D metabolism, and matrix mineralization (Addison et al. [@CR3]; Brownstein et al. [@CR21]). The C3HeB/FeJ-Phex^BAP012^ and C3HeB/FeJ-Phex^BAP024^ mutant lines represent two new mutant mouse lines with novel point mutations modeling XLHR in addition to previously published models (Carpinelli et al. [@CR23]; Lorenz-Depiereux et al. [@CR70]; Xiong et al. [@CR114]).

New point mutations of the *Casr* gene were found in seven mouse lines. The large extracellular domain of the receptor contains clusters of amino acid residues, which may be involved in calcium binding (Brown et al. [@CR20]). Exon 7 encodes the seven transmembrane domains and four intracellular loops of CASR (Chang et al. [@CR24]). Human *CASR* mutations are known to be causative for primary hyperparathyroidism (HP) (Bilezikian et al. [@CR17]) and familial benign hypocalciuric hypercalcemia (FHH) (Pollak et al. [@CR92]). Approximately two thirds of FHH patients showed loss-of-function mutations involving the 3,234-bp coding region of the *CASR* gene (D'Souza-Li et al. [@CR29]). Individuals with HP and FHH discriminate in creatinine clearance and serum magnesium values, both being higher in FHH (Marx et al. [@CR80]). It has been demonstrated that individuals with FHH are heterozygous, and children within these families with severe neonatal primary hyperparathyroidism (NSHPT) are homozygous for *CASR* mutations (Janicic et al. [@CR59]; Pollak et al. [@CR91]). Mice with tissue-specific deletion of *Casr* in the parathyroid gland and bone exhibited profound bone defects (Chang et al. [@CR24]). C3H;102Casr^Nuf^/H mice carry an activating ENU-derived *Casr* point mutation that exhibits hypocalcemia, hyperphosphatemia, cataracts, and ectopic calcifications (Hough et al. [@CR52]). We obtained the first presumed loss-of-function point mutation isolated in C3HeB/FeJ-Casr^BCH002^ mice that is supposed to model human FHH. Since the mouse line has been bred more than 15 generations and because we found six other independent *Casr* mutations for this phenotype, it is more than likely that the consistent phenotype is due to the isolated point mutation of the *Casr* gene. Heterozygous C3HeB/FeJ-Casr^BCH002^ mice exhibited high Ca and PTH values similar to targeted Black Swiss/129SvJ *Casr*^+/−^ and *Casr*^−/−^ mice (Ho et al. [@CR50]), but, in addition, they showed enlarged parathyroid glands described only for *Casr*^−/−^ mice. Further heterozygous intercrosses are required to find out if homozygous C3HeB/FeJ-Casr^BCH002^ mice are viable, which is not the case in *Casr*^−/−^ mice. This would raise the opportunity to obtain a mouse model for NSHPT. More than 270 mutations have been described so far in the human *CASR* mutation database ([www.casrdb.mcgill.ca](http://www.casrdb.mcgill.ca); Nakajima et al. [@CR86]), and interestingly most of the human mutations were found in exons 4 and 7. The mouse lines carrying *Casr* mutations obtained in our screen showed slight differences in the expression of the phenotype. Additional studies on phenotypical and histological traits will help to discriminate between the different effects of each point mutation on the severity of hyperparathyroidism and concomitantly to improve our understanding of *CASR* mutations in human patients.

Heterozygous C3HeB/FeJ-Alpl^BAP032^ mice showed a statistically significant reduction of ALP activity in plasma without additional phenotypes, as observed in heterozygous *Akp2*^*Hpp*/+^mice derived in an ENU mutagenesis screen on C3H/HeH background (Hough et al. [@CR53]). In *Akp2*^*Hpp*/+^ mice, an *Alpl* loss-of-function mutation led to the rare disease hypophosphatasia (HPP) which displays reduction of plasma ALP activities to about 50 % in *Akp2*^*Hpp*/+^ and a stronger reduction in *Akp2*^*Hpp*/*Hpp*^ mice. *Akp2*^*Hpp*/+^ mice were radiographically and histologically indistinguishable from wild-type mice at different time points, as were 16-week-old C3HeB/FeJ-Alpl^BAP032^ mice in DEXA and X-ray analysis. Interestingly, we observed a stronger ALP reduction in heterozygous C3HeB/FeJ-Alpl^BAP032^ mice than in *Akp2*^*Hpp*/+^mice, with ALP activities in female and male mutant mice reduced to 29 % of that found in wild-type littermates. Severe HPP forms are characterized by hypomineralization, rickets, seizures, and nephrocalcinosis due to hypercalciuria (Beck et al. [@CR15]). *Alpl*^−/−^ mice showed a reduction in body size, no detectable ALP levels, and lethality prior to weaning, whereas *Alpl*^+/−^ mice appeared healthy (Narisawa et al. [@CR87]). The identical point mutation of C3HeB/FeJ-Alpl^BAP032^ mice has also been described for a patient with HPP (Taillandier et al. [@CR106]). Heterozygous C3HeB/FeJ-Alpl^BAP032^ mice presumably model mild adult HPP. The mouse line was bred for more than ten generations, showing full penetrance of the phenotype in all litters. A multitude of diverse point mutations, deletions, and insertions of the human *TNSALP* gene causing HPP are listed in the hypophosphatasia database ([www.sesep.uvsq.fr/03_hypo_mutations.php](http://www.sesep.uvsq.fr/03_hypo_mutations.php)). The diversity of published human point mutations emphasizes the importance of mouse models for further investigations on physiological functions and cellular mechanisms of *Alpl* regions involved in collagen and Ca binding. Interestingly, we isolated in addition one silent mutation in the BAP020 mouse line (Table [4](#Tab4){ref-type="table"}) showing the expected phenotype. No additional *Alpl* mutations were found in this mouse line. *Alpl* mRNA and translation of ALP were not analyzed so far.

Since only total ALP can be tested in mice so far, we probably will isolate mouse lines showing alterations other than the bone ALP isoform. High alterations of plasma ALP activities without any additional phenotypes, as observed in homozygous animals of the C3HeB/FeJ-Asgr1^BAP005^ line, have not been published in mice before. It has been described in patients with chronic liver disease that the adult intestinal ALP isoenzyme was increased due to the reduced efficiency or numbers of asialoglycoprotein receptors (Moss [@CR85]). Thus, the mutation of the gene in BAP005 mice seems to cause alterations of the intestinal ALP isoform as a secondary effect. *ASRG1* mutations may be responsible for high ALP activities of so far unknown reasons in humans without any skeletal disorders (Panteghini [@CR89]) or may cause benign familial hyperphosphatasemia (Siraganian et al. [@CR99]).

We have to consider bone as an active metabolic organ with a possible influence on metabolism in diseases of disturbed bone turnover (Ferron et al. [@CR41]; Fulzele et al. [@CR47]). For this reason, systematic analysis of all organ systems, as in the German Mouse Clinic (Gailus-Durner et al. [@CR48]), might provide new insights into the actions in these pathways. Our mouse models will be archived by the European Mouse Mutant Archive (EMMA) and are available ([www.emmanet.org](http://www.emmanet.org)) for the scientific community.
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